Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | EED | O75530 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037448 | 1.00 | HTR2C (0.69) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL2863498 | 1.00 | HTR2C (0.69) | HTR2CEEDDRD2DRD3HTR2A | |
| Hydrochloric Acid SCHEMBL567518 | 0.98 | HTR2C (0.70) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL11258120 | 0.95 | HTR2C (0.68) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL1810242 | 0.92 | HTR2C (0.82) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL8049667 | 0.92 | HTR2C (0.82) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL8032211 | 0.92 | HTR2C (0.82) | HTR2CEEDDRD2DRD3HTR2A | |
| Hydrochloric Acid SCHEMBL4573066 | 0.91 | HTR2C (0.82) | HTR2CEEDDRD2HTR2A | |
| SCHEMBL22667384 | 0.85 | HTR2C (0.70) | HTR2CDRD2HTR2A | |
| SCHEMBL18937877 | 0.84 | DRD2 (0.57) | HTR2CEEDDRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910353-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007030089-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | WO | claimed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-0175452-A1 | 1,3-Disubstituted piperidine compounds as neuroleptic agents | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| EP-0175452-A1 | 1,3-Disubstituted piperidine compounds as neuroleptic agents | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| EP-0114603-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1984-08-01 | — | — | EP | disclosed |
| EP-0105243-A2 | Separation of racemic 1-propyl-3-aryl piperidines | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-04-11 | — | — | EP | disclosed |
| US-4426386-A | CNS DISORDERS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1984-01-17 | — | — | US | disclosed |
| EP-0097628-A2 | Piperidine derivatives, processes for their preparation and pharmaceutical preparation containing them | Carlsson, Per Arvid Emil (SE) | 1984-01-04 | — | — | EP | disclosed |
| EP-0084920-A2 | New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes | Carlsson, Per Arvid Emil (SE) | 1983-08-03 | — | — | EP | disclosed |
| EP-0030526-A1 | New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds | Astra Läkemedel Aktiebolag (SE) | 1981-06-17 | — | — | EP | disclosed |
| WO-1981001552-A1 | NEW PHENYL-AZACYCLOALKANES | ASTRA LAEKEMEDEL AB (SE) | 1981-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | HTR2C 4642/4885EED 4885/4885DRD2 3854/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR2C 4185/4885EED 4381/4885DRD2 4505/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | HTR2C 4074/4885EED 2034/4885DRD2 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.